TDAC
Translational·NASDAQ
--
--(--)
--
--(--)
TDAC fundamentals
During Q4 2025, Translational (TDAC) reported revenue of --, a YoY change of 0.00%. Net income was 1.60M, a YoY change of 19939.50%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Cost of Goods and Services | -- -- | 485.55K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 500 -- | -1.70K -- | 0 -- | 1.69K -- | 61.28K +12156.60% | 133.39K +7928.05% | 347.41K -- | 221.13K +13023.26% | 213.66K +248.64% | 162.34K +21.71% | 944.54K -- |
Selling, General and Administrative Expenses | 500 -- | -1.70K -- | 0 -- | 1.69K -- | 61.28K +12156.60% | 133.39K +7928.05% | 347.41K -- | 221.13K +13023.26% | 213.66K +248.64% | 162.34K +21.71% | 944.54K -- |
General and Administrative Expenses | 1.70K -- | -1.70K -- | 0 -- | 1.69K -- | 61.28K +3496.42% | 133.39K +7928.05% | 347.41K -- | 221.13K +13023.26% | 213.66K +248.64% | 162.34K +21.71% | 944.54K -- |
Operating Income | -500 -- | -483.85K -- | 0 -- | -1.69K -- | -61.28K -12156.60% | -133.39K +72.43% | -347.41K -- | -221.13K -13023.26% | -213.66K -248.64% | -162.34K -21.71% | -944.54K -- |
Non-Operating Income (Loss) | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | 125.35K -- | 1.83M -- | 1.84M -- | 1.87M -- | 1.76M +1302.70% | 7.31M -- |
Gain (Loss) on Other Investment | -- -- | 0 -- | 0 -- | -- -- | -- -- | 125.35K -- | 1.83M -- | -- -- | -- -- | 7.31M +5729.44% | -- -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 1.84M -- | 0 -- | 125.35K -- | -- -- |
Net Interest Expense | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -1.87M -- | 5.67M -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 1.87M -- | -5.67M -- | -- -- |
Pretax Income From Continuing Operations | -500 -- | -483.85K -- | -- -- | -1.69K -- | -61.28K -12156.60% | -8.04K +98.34% | 1.48M -- | 1.62M +96440.77% | 1.66M +2808.94% | 1.60M +19939.50% | 6.36M -- |
Net Income | -500 -- | -483.85K -- | -- -- | -1.69K -- | -61.28K -12156.60% | -8.04K +98.34% | 1.48M -- | 1.62M +96440.77% | 1.66M +2808.94% | 1.60M +19939.50% | 6.36M -- |
Net Income Attributable to Owners of the Company | -500 -- | -483.85K -- | 0 -- | -1.69K -- | -61.28K -12156.60% | -8.04K +98.34% | 1.48M -- | 1.62M +96440.77% | 1.66M +2808.94% | 1.60M +19939.50% | 6.36M -- |
Net Income Attributable to Common Stockholders | -500 -- | -483.85K -- | 0 -- | -1.69K -- | -61.28K -12156.60% | -8.04K +98.34% | 1.48M -- | 1.62M +96440.77% | 1.66M +2808.94% | 1.60M +19939.50% | 6.36M -- |
Total Comprehensive Income Attributable to Owners of the Company | -1.70K -- | -483.85K -- | 0 -- | -1.69K -- | -- -- | -- -- | 1.48M -- | 1.62M +96440.77% | -- -- | -- -- | -- -- |
Basic EPS | -- -- | -- -- | -- -- | 0 -- | -0.02 -- | 0 -- | 0.07 -- | 0.07 -- | 0.08 +500.00% | 0.07 -- | 0.29 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | 0 -- | 0 -- | -0.02 -- | -- -- | 0.07 -- | 0.07 -- | 0.08 +500.00% | -- -- | -- -- |
Diluted EPS | -- -- | -- -- | -- -- | 0 -- | -0.02 -- | -- -- | 0.07 -- | 0.07 -- | 0.08 +500.00% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | 0 -- | 0 -- | -0.02 -- | -- -- | 0.07 -- | 0.07 -- | 0.08 +500.00% | -- -- | -- -- |
You can ask Aime
What factors drove the changes in Translational's revenue and profit?What does Translational do and what are its main business segments?What is Translational's gross profit margin?What guidance did Translational's management provide for the next earnings period?Did Translational beat or miss consensus estimates last quarter?What were the key takeaways from Translational’s earnings call?What were the key takeaways from Translational's earnings call?What is Translational's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
